Simmons David
Department of Rural Health, Faculty Medicine Dentistry and Health Sciences, University of Melbourne, PO Box 6500, Shepparton, Victoria 3632, Australia.
Curr Diab Rep. 2002 Aug;2(4):331-6. doi: 10.1007/s11892-002-0023-4.
The quest for tight glucose control has led to the development of insulin analogues (insulin lispro, insulin aspart, insulin glargine) designed to optimize glucose control while minimizing the impact of insulin therapy on daily life. Women with diabetes are increasingly likely to become pregnant on these new products and to benefit from their use while pregnant. Caution over the use of new medications in pregnancy has limited experience, but increasing evidence is emerging that use of insulin lispro is not associated with excess risk of fetal malformations, is associated with similar or better outcomes during pregnancy, and is preferred over regular insulin. Similar evidence for the other insulin analogues has yet to emerge, but is unlikely to be dissimilar.
对严格血糖控制的追求促使了胰岛素类似物（赖脯胰岛素、门冬胰岛素、甘精胰岛素）的研发，这些胰岛素类似物旨在优化血糖控制，同时将胰岛素治疗对日常生活的影响降至最低。糖尿病女性使用这些新产品后怀孕的可能性越来越大，并且在孕期使用能从中获益。由于对孕期使用新药持谨慎态度，相关经验有限，但越来越多的证据表明，使用赖脯胰岛素与胎儿畸形风险增加无关，在孕期的结局相似或更好，并且比常规胰岛素更受青睐。其他胰岛素类似物的类似证据尚未出现，但情况不太可能不同。
